US regulator warns Novo Nordisk’s Metsera offer ‘may violate’ antitrust law
Federal Trade Commission wants to ensure bid for weight-loss biotech addresses competition concerns
Related reading
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Pfizer wins $10bn bidding war for weight-loss start-up Metsera
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera
Pfizer had struck deal in September to buy obesity-focused biotech
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies
Improved pitches from both large pharma groups expected to be revealed later on Tuesday
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most